DK1333853T3 - Vækstfaktorkompleks - Google Patents

Vækstfaktorkompleks

Info

Publication number
DK1333853T3
DK1333853T3 DK01971494.8T DK01971494T DK1333853T3 DK 1333853 T3 DK1333853 T3 DK 1333853T3 DK 01971494 T DK01971494 T DK 01971494T DK 1333853 T3 DK1333853 T3 DK 1333853T3
Authority
DK
Denmark
Prior art keywords
growth factor
factor complex
complex
growth
factor
Prior art date
Application number
DK01971494.8T
Other languages
English (en)
Inventor
Jennifer Ann Kricker
Zee Upton
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of DK1333853T3 publication Critical patent/DK1333853T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
DK01971494.8T 2000-09-22 2001-09-24 Vækstfaktorkompleks DK1333853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR0309A AUPR030900A0 (en) 2000-09-22 2000-09-22 Growth factor complex
PCT/AU2001/001196 WO2002024219A1 (en) 2000-09-22 2001-09-24 Growth factor complex

Publications (1)

Publication Number Publication Date
DK1333853T3 true DK1333853T3 (da) 2012-11-05

Family

ID=3824376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01971494.8T DK1333853T3 (da) 2000-09-22 2001-09-24 Vækstfaktorkompleks

Country Status (11)

Country Link
US (4) US7514398B2 (da)
EP (3) EP2385064A3 (da)
JP (1) JP5165176B2 (da)
KR (1) KR100898765B1 (da)
CN (2) CN102940880A (da)
AU (1) AUPR030900A0 (da)
CA (1) CA2424394C (da)
DK (1) DK1333853T3 (da)
ES (1) ES2392505T3 (da)
NZ (1) NZ525302A (da)
WO (1) WO2002024219A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
WO2002060163A2 (en) * 2000-10-24 2002-08-01 Andress Dennis L Methods for increasing bone formation and enhancing bone accretion
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US20100143442A1 (en) * 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2004208856B2 (en) * 2003-02-05 2009-06-04 Factor Therapeutics Limited Growth factor complexes and modulation of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
ATE459637T1 (de) * 2004-12-24 2010-03-15 Insmed Inc Gereinigte rhigf-i/rhigfbp-3-komplexe und herstellungsverfahren dafür
EP2076589B1 (en) 2006-10-02 2017-02-22 Orthocell Limited A method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair
CN101970642A (zh) * 2007-09-04 2011-02-09 昆士兰技术大学 无饲养细胞培养基和系统
ES2629853T3 (es) * 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
CN102448484A (zh) * 2009-04-01 2012-05-09 医学研究，基础设施和卫生服务基金的特拉维夫医疗中心 调节角质化细胞增生和分化的方法
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
KR101187814B1 (ko) * 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
EP2922862B1 (en) * 2012-11-22 2019-01-02 Factor Therapeutics Limited Complex-formation-modulating agents and uses therefor
JP2017501970A (ja) * 2013-12-10 2017-01-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 薬学的活性エンティティのマルチサブユニット構造への標的特異的送達のためのマルチサブユニット構造のサブユニットの結合ドメインの使用
DK3082466T3 (da) * 2013-12-18 2019-10-07 Thylabisco Ab Anvendelse af thylakoider til formindskelse af trangen til velsmagende næringsmidler
KR101596635B1 (ko) * 2015-05-19 2016-02-23 중앙대학교 산학협력단 Igfbp2를 유효성분으로 함유하는 군날개 예방 또는 치료용 약학조성물
EP3576769A4 (en) * 2017-02-06 2021-01-13 Amolyt Pharma COMPOUNDS, COMPOSITIONS, AND USES THEREOF FOR IMPROVEMENT OF BONE DISEASES
CN107670105B (zh) * 2017-09-29 2018-10-30 中国人民解放军陆军军医大学第一附属医院 Igfbp3在制备骨缺损修复材料中的应用
WO2019224786A1 (en) 2018-05-24 2019-11-28 Alize Pharma Iii Sas Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders
CN111289756A (zh) * 2018-12-10 2020-06-16 北京师范大学 卵巢癌肺转移成瘤相关的尿液标志物
CN110526958B (zh) * 2019-07-22 2022-04-29 广州暨南大学医药生物技术研究开发中心有限公司 一种活力修复肽Tvigour A及其应用
CN117451995A (zh) * 2021-12-06 2024-01-26 上海市精神卫生中心（上海市心理咨询培训中心） 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US5973115A (en) 1987-05-15 1999-10-26 Amgen Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5144847A (en) 1988-03-24 1992-09-08 Johann Zach Pressure or force measuring device
CA1341598C (en) 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5407813A (en) * 1990-05-01 1995-04-18 Gold Biotechnology Preparation of nucleic acid deletion fragments
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン，インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
CA2090705A1 (en) * 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
US5958764A (en) 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
AU6136694A (en) 1993-02-12 1994-08-29 Repligen Corporation Methods for generating broadly neutralizing anti-hiv antibodies and antigens capable of eliciting same
CN1134111A (zh) * 1993-04-07 1996-10-23 赛纳根公司 使用胰岛素样生长因子结合蛋白质的方法
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
WO1994028009A1 (en) * 1993-06-01 1994-12-08 Ludwig Institute For Cancer Research Fragments of neurofibromin (nf1) and method to reverse activated ras induced malignant transformation in mammalian cells
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US6143495A (en) 1995-11-21 2000-11-07 Yale University Unimolecular segment amplification and sequencing
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
WO1998024922A1 (en) * 1996-12-02 1998-06-11 Valentis, Inc. Insulin-like growth factor i (igf-i) expression system and methods of use
US5914390A (en) * 1997-05-12 1999-06-22 Celtrix Pharmaceuticals, Inc. Methods for increasing yields of recombinant proteins
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU3192299A (en) 1998-03-18 1999-10-11 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
AU767141B2 (en) * 1998-10-02 2003-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
DE60042550D1 (de) 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
AU3897200A (en) 1999-03-18 2000-10-04 Hope Heart Institute, The Endothelial cell stimulation by a complex of fibronectin and vascular endothelial growth factor
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex

Also Published As

Publication number Publication date
NZ525302A (en) 2005-02-25
EP2385064A2 (en) 2011-11-09
AUPR030900A0 (en) 2000-10-12
CN1541107A (zh) 2004-10-27
CA2424394A1 (en) 2002-03-28
CN1541107B (zh) 2013-03-20
US7514398B2 (en) 2009-04-07
US20100279927A1 (en) 2010-11-04
EP1333853A4 (en) 2008-03-26
US8563507B2 (en) 2013-10-22
EP2385063A3 (en) 2012-02-29
US20040049017A1 (en) 2004-03-11
JP2004510711A (ja) 2004-04-08
WO2002024219A1 (en) 2002-03-28
HK1070290A1 (en) 2005-06-17
US8933027B2 (en) 2015-01-13
US20140045749A1 (en) 2014-02-13
EP1333853A1 (en) 2003-08-13
EP2385064A3 (en) 2012-02-29
CA2424394C (en) 2017-05-23
EP1333853B1 (en) 2012-08-01
US7785835B2 (en) 2010-08-31
CN102940880A (zh) 2013-02-27
US20070243226A1 (en) 2007-10-18
JP5165176B2 (ja) 2013-03-21
EP2385063A2 (en) 2011-11-09
ES2392505T3 (es) 2012-12-11
KR20030063344A (ko) 2003-07-28
KR100898765B1 (ko) 2009-05-20

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATA2932001A (de) Schneefräse
DK1524272T3 (da) Væksthormonsekretionsfremmere
EE200200420A (et) Linesoliid - kristallivorm II
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE10192638T1 (de) Bohrstangenladevorrichtung
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE60030011D1 (de) Umpflanzungsmaschine
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
NO20011665D0 (no) Aviksboringssystem
NO20026086L (no) Transgent produsert plateavledet vekstfaktor
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE50007634D1 (de) Kardioplegieballonkatheter
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195909T1 (de) Viehfüttervorrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE10195992T1 (de) Oberflächenendbearbeitungsbelag